{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:34:01Z","timestamp":1759847641484},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1007\/s11910-001-0085-8","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T12:25:37Z","timestamp":1180700737000},"page":"320-328","source":"Crossref","is-referenced-by-count":11,"title":["Parkinson\u2019s disease: The treatment of drug-induced hallucinations and psychosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Eric S.","family":"Molho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart A.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"85_CR1","first-page":"391","volume-title":"Advances in Neurology, vol. 53: PD: Anatomy, Pathology and Therapy","author":"P Fischer","year":"1990","unstructured":"Fischer P, Danielczyk W, Simanyi M, Streifler MB: Dopaminergic psychosis in advanced Parkinson\u2019s disease. In Advances in Neurology, vol. 53: PD: Anatomy, Pathology and Therapy. Edited by Streifler MB, Korczyn AD, Melamed E, Youdim MB. New York: Raven Press; 1990:391\u2013397."},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 1993, 43:2227\u20132229.","journal-title":"Neurology"},{"key":"85_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","volume":"45","author":"CG Goetz","year":"1995","unstructured":"Goetz CG, Stebbins GT: Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s disease. Neurology 1995, 45:669\u2013671.","journal-title":"Neurology"},{"key":"85_CR4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1532-5415.1991.tb03627.x","volume":"33","author":"JL Cummings","year":"1991","unstructured":"Cummings JL: Behavioral complications of drug treatment of Parkinson\u2019s disease. J Am Geriatr Soc 1991, 33:708\u2013716.","journal-title":"J Am Geriatr Soc"},{"key":"85_CR5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"The Parkinson Study Group","year":"1999","unstructured":"The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med 1999, 340:757\u2013763. The first large, double-blind, placebo-controlled trial that confirmed the results of numerous open-label reports. It showed that clozapine dramatically improves psychosis in Parkinson\u2019s disease patients without worsening parkinsonism.","journal-title":"N Engl J Med"},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3928\/0048-5713-19780901-08","volume":"8","author":"HL Klawans","year":"1978","unstructured":"Klawans HL: Levodopa-induced psychosis. Psychiatric Ann 1978, 8:447\u2013451.","journal-title":"Psychiatric Ann"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","volume":"53","author":"JR Sanchez-Ramos","year":"1996","unstructured":"Sanchez-Ramos JR, Ortoll R, Paulson GW: Visual hallucinations associated with Parkinson\u2019s disease. Arch Neurol 1996, 53:1265\u20131268.","journal-title":"Arch Neurol"},{"key":"85_CR8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"C Moskovitz","year":"1978","unstructured":"Moskovitz C, Moses H, Klawans HL: Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978, 135:669\u2013675.","journal-title":"Am J Psychiatry"},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson\u2019s disease. Arch Neurol 1999,56, 595\u2013601.","journal-title":"Arch Neurol"},{"key":"85_CR10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","volume":"64","author":"R Inzelberg","year":"1998","unstructured":"Inzelberg R, Kipervasser S, Korczyn AD: Auditory hallucinations in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1998, 64:533\u2013535.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"85_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002826-198205020-00003","volume":"5","author":"PA Nausieda","year":"1982","unstructured":"Nausieda PA, Weiner WJ, Kaplan LR, et al.: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982, 5:183\u2013194.","journal-title":"Clin Neuropharmacol"},{"key":"85_CR12","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 3, revised. Washington, DC: American Psychiatric Association; 1987.","edition":"edn 3"},{"key":"85_CR13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1176\/jnp.10.2.194","volume":"10","author":"DM Roane","year":"1998","unstructured":"Roane DM, Rogers JD, Robinson JH, Feinberg TE: Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci 1998, 10:194\u2013198.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"85_CR14","first-page":"60","volume":"31","author":"JA Yaryura-Tobias","year":"1970","unstructured":"Yaryura-Tobias JA, Diamond B, Merlis S: Psychiatric manifestations of levodopa. Dis Nerv Syst 1970, 31:60\u201363.","journal-title":"Dis Nerv Syst"},{"key":"85_CR15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","volume":"218","author":"FK Goodwin","year":"1971","unstructured":"Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 1971, 218:1915\u20131920.","journal-title":"JAMA"},{"key":"85_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.410020207","volume":"2","author":"HL Klawans","year":"1977","unstructured":"Klawans HL, Goetz CG, Nausieda PA, Weiner WJ: Levodopainduced dopamine receptor hypersensitivity. Ann Neurol 1977, 2:125\u2013129.","journal-title":"Ann Neurol"},{"key":"85_CR17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/0003-4819-111-3-218","volume":"111","author":"WE Golden","year":"1989","unstructured":"Golden WE, Lavender RC, Metzer WS: Acute postoperative confusion and hallucinations in Parkinson\u2019s disease. Ann Intern Med 1989, 111:218\u2013222.","journal-title":"Ann Intern Med"},{"key":"85_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-407-02295-9.50006-0","volume-title":"Movement Disorders","author":"CD Marsden","year":"1981","unstructured":"Marsden CD, Fahn S: Problems in PD. In Movement Disorders. Edited by Marsden CD, Fahn S. London: Butterworth Scientific; 1981:1\u20137."},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archinte.1985.00360050183031","volume":"145","author":"JH Friedman","year":"1985","unstructured":"Friedman JH: \"Drug Holidays\" in the treatment of Parkinson\u2019s disease: a brief review. Arch Intern Med 1985, 145:913\u2013915.","journal-title":"Arch Intern Med"},{"key":"85_CR20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.39.9.1219","volume":"39","author":"JH Friedman","year":"1989","unstructured":"Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson\u2019s disease. Neurology 1989, 39:1219\u20131221.","journal-title":"Neurology"},{"key":"85_CR21","first-page":"740","volume":"324","author":"RJ Baldesserini","year":"1991","unstructured":"Baldesserini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. N Engl J Med 1991, 324:740\u2013754.","journal-title":"N Engl J Med"},{"key":"85_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","volume":"12","author":"SA Factor","year":"1997","unstructured":"Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483\u2013496.","journal-title":"Mov Disord"},{"key":"85_CR23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","unstructured":"French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet 1999, 353:2041\u20132042. A second multicenter, double-blind trial performed in Europe that confirmed that clozapine could be used safely and effectively to treat drug-induced psychosis in Parkinson\u2019s disease.","journal-title":"Lancet"},{"key":"85_CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","volume":"235","author":"E Scholz","year":"1985","unstructured":"Scholz E, Dichgans J: Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985, 235:60\u201364.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"85_CR25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, et al.: Clozapineinduced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993, 329:162\u2013167.","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"85_CR26","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, et al.: Reducing clozapinerelated morbidity and mortality: 5 years experience with the Clozaril National Registry. J Clin Psychiatry 1998, 59(suppl 3):3\u20139.","journal-title":"J Clin Psychiatry"},{"key":"85_CR27","first-page":"703","volume":"60","author":"P Greene","year":"1993","unstructured":"Greene P, Cote L, Fahn S: Treatment of drug-induced psychosis in Parkinson\u2019s disease with clozapine. Adv Neurol 1993, 60:703\u2013706.","journal-title":"Adv Neurol"},{"key":"85_CR28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","volume":"15","author":"JH Friedman","year":"2000","unstructured":"Friedman JH, Factor SA: Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease. Mov Disord 2000, 15:201\u2013211. A comprehensive critical review of the literature concerning the use of atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease.","journal-title":"Mov Disord"},{"key":"85_CR29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","volume":"343","author":"G Meco","year":"1994","unstructured":"Meco G, Alessandria A, Bonifati V, Giustini P: Risperidone for hallucinations in levodopa-treated Parkinson\u2019s disease patients. Lancet 1994, 343:1370\u20131371.","journal-title":"Lancet"},{"key":"85_CR30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","volume":"344","author":"B Ford","year":"1994","unstructured":"Ford B, Lynch T, Greene P: Risperidone in Parkinson\u2019s disease. Lancet 1994, 344:681.","journal-title":"Lancet"},{"key":"85_CR31","first-page":"556","volume":"56","author":"SS Rich","year":"1995","unstructured":"Rich SS, Friedman JH, Ott BR: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995, 56:556\u2013559.","journal-title":"J Clin Psychiatry"},{"key":"85_CR32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","volume":"12","author":"G Meco","year":"1997","unstructured":"Meco G, Alessandria A, Giustini P, Bonifati V: Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: an open-label, long-term study. Mov Disord 1997, 12:610\u2013611.","journal-title":"Mov Disord"},{"key":"85_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(95)91245-2","volume":"346","author":"RL Allen","year":"1995","unstructured":"Allen RL, Walker Z, D\u2019ath PJ, Katona LE: Risperidone for psychotic and behavioral symptoms in Lewy body dementia. Lancet 1995, 346:185.","journal-title":"Lancet"},{"key":"85_CR34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","volume":"346","author":"IG McKeith","year":"1995","unstructured":"McKeith IG, Ballard CG, Harrison RW: Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995, 346:699.","journal-title":"Lancet"},{"key":"85_CR35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","volume":"9","author":"RJ Workman Jr","year":"1997","unstructured":"Workman RJ Jr, Orengo CA, Bakey AA, et al.: The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1997, 9:594\u2013597.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"85_CR36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1531-8257(200003)15:2<301::AID-MDS1014>3.0.CO;2-2","volume":"15","author":"NA Leopold","year":"2000","unstructured":"Leopold NA: Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000, 15:301\u2013304.","journal-title":"Mov Disord"},{"key":"85_CR37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","volume":"15","author":"E Mohr","year":"2000","unstructured":"Mohr E, Mendis T, Hildebrand IC, DeDeyn PP: Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: An open pilot trial. Mov Disord 2000, 15:1230\u20131237.","journal-title":"Mov Disord"},{"key":"85_CR38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","volume":"47","author":"EC Wolters","year":"1996","unstructured":"Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease. Neurology 1996, 47:1085\u20131087.","journal-title":"Neurology"},{"key":"85_CR39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1212\/WNL.50.4.1183-a","volume":"50","author":"FJ Jimenez-Jimenez","year":"1998","unstructured":"Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, et al.: Olanzapine can worsen parkinsonism. Neurology 1998, 50:1183\u20131184.","journal-title":"Neurology"},{"key":"85_CR40","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1212\/WNL.50.4.1195-a","volume":"50","author":"JH Friedman","year":"1998","unstructured":"Friedman JH: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease [letter]. Neurology 1998, 50:1195\u20131196.","journal-title":"Neurology"},{"key":"85_CR41","first-page":"285","volume":"21","author":"JH Friedman","year":"1998","unstructured":"Friedman JH, Goldstein SM, Jacques C: Substituting clozapine for olanzapine in psychiatrically stable Parkinson\u2019s disease patients; Results of an open-label pilot trial. Clin Neuropharmacol 1998, 21:285\u2013288.","journal-title":"Clin Neuropharmacol"},{"key":"85_CR42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9","volume":"14","author":"ES Molho","year":"1999","unstructured":"Molho ES, Factor SA: Worsening of motor features of Parkinson\u2019s disease with olanzapine. Mov Disord 1999, 14:1014\u20131016.","journal-title":"Mov Disord"},{"key":"85_CR43","first-page":"862","volume":"13","author":"WJ Weiner","year":"1998","unstructured":"Weiner WJ, Minagar A, Shulman LM: Olanzapine for the treatment of hallucinations\/delusions in Parkinson\u2019s disease. Mov Disord 1998, 13:862.","journal-title":"Mov Disord"},{"key":"85_CR44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp.65.5.774","volume":"65","author":"JM Graham","year":"1998","unstructured":"Graham JM, Sussman JD, Ford KS, Sagar HJ: Olanzapine in the treatment of hallucinosis in idiopathic Parkinson\u2019s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998, 65:774\u2013777.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 2","key":"85_CR45","first-page":"A215","volume":"52","author":"NP Stover","year":"1999","unstructured":"Stover NP, Juncos JL: Olanzapine treatment of parkinsonian patients with psychosis. Neurology 1999, 52(suppl 2):A215.","journal-title":"Neurology"},{"key":"85_CR46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","volume":"55","author":"CG Goetz","year":"2000","unstructured":"Goetz CG, Blasucci CM, Leurgans S, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating Parkinson\u2019s disease patients. Neurology 2000, 55:789\u2013794. This double-blind comparison seems to have resolved the confusion caused by conflicting results in previous open-label trials by showing that olanzapine was significantly more likely to cause worsening of Parkinson\u2019s disease motor symptoms than clozapine.","journal-title":"Neurology"},{"key":"85_CR47","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1212\/WNL.50.4.1196","volume":"50","author":"EC Wolters","year":"1998","unstructured":"Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease. Neurology 1998, 50[letter]:1196.","journal-title":"Neurology"},{"key":"85_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.10.2.216","volume":"10","author":"MA Parsa","year":"1998","unstructured":"Parsa MA, Bastani B: Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1998, 10:1\u20134.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"85_CR49","first-page":"595","volume":"11","author":"ML Evatt","year":"1996","unstructured":"Evatt ML, Jewart D, Juncos JL: \"Seroquel\" (ICI 204,636) treatment of psychosis in Parkinsonism. Mov Disord 1996, 11:595.","journal-title":"Mov Disord"},{"issue":"suppl 4","key":"85_CR50","first-page":"A70","volume":"50","author":"JL Juncos","year":"1998","unstructured":"Juncos JL, Evatt ML, Jewert D: Long term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998, 50(suppl 4):A70-A71.","journal-title":"Neurology"},{"issue":"suppl 2","key":"85_CR51","first-page":"A262","volume":"52","author":"JL Juncos","year":"1999","unstructured":"Juncos JL, Arvanitis L, Sweitzer D, et al.: Quetiapine improves psychotic symptoms associated with Parkinson\u2019s disease. Neurology 1999, 52(suppl 2):A262.","journal-title":"Neurology"},{"key":"85_CR52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004714-200002000-00010","volume":"20","author":"SD Targum","year":"2000","unstructured":"Targum SD, Abbott JL: Efficacy of quetiapine in Parkinson\u2019s patients with psychosis. J Clin Psychopharmacol 2000, 20:54\u201360.","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 2","key":"85_CR53","first-page":"274","volume":"13","author":"J Samanta","year":"1998","unstructured":"Samanta J, Stacy M: Quetiapine in the treatment of hallucinations in advanced Parkinson\u2019s disease. Mov Disord 1998, 13(suppl 2):274.","journal-title":"Mov Disord"},{"key":"85_CR54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","volume":"14","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH, Jacques C, Rosenfeld M: Quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s Disease. Mov Disord 1999, 14:484\u2013487. A large, open-label trial that demonstrated that quetiapine effectively treats drug-induced psychosis in Parkinson\u2019s disease with minimal risk of motor deterioration.","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"85_CR55","first-page":"A215","volume":"52","author":"JH Friedman","year":"1999","unstructured":"Friedman JH, Fernandez HH, Jacques C, Rosenfeld M: Quetiapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. Neurology 1999, 52(suppl 2):A215.","journal-title":"Neurology"},{"key":"85_CR56","first-page":"1040","volume":"15","author":"SA Factor","year":"2000","unstructured":"Factor SA, Reddy S, Molho ES, Feustel PJ: The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2000, 15:1040.","journal-title":"Mov Disord"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-001-0085-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-001-0085-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-001-0085-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T13:09:28Z","timestamp":1628946568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-001-0085-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s11910-001-0085-8","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}